Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23479398)

  • 1. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
    Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
    Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
    Schipani A; Back D; Owen A; Davies G; Khoo S; Siccardi M
    Clin Pharmacokinet; 2015 Jan; 54(1):107-16. PubMed ID: 25245943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.
    McCance-Katz EF; Gruber VA; Beatty G; Lum P; Ma Q; DiFrancesco R; Hochreiter J; Wallace PK; Faiman MD; Morse GD
    Am J Addict; 2014; 23(2):137-44. PubMed ID: 24118434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
    Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz.
    McCance-Katz EF; Gruber VA; Beatty G; Lum PJ; Rainey PM
    J Addict Med; 2013; 7(4):264-70. PubMed ID: 23666322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
    Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
    Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
    King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    Rekić D; Röshammar D; Mukonzo J; Ashton M
    Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.